Skip to main content
OpenTrials

Clinical trial condition

HCV Infection

Explore clinical trials studying HCV Infection. Study availability and eligibility vary by location and protocol.

45 public trials 1 recruiting study
Refine in advanced search Browse all conditions

HCV Infection trial results

Completed

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00978497

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • United States, California 1 Anaheim, California, United States
  • United States, California 4 Los Angeles, California, United States
  • United States, California 2 San Clemente, California, United States
  • United States, California 3 San Diego, California, United States
View all 21 locations
View Trial Details
Completed

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

NCT00726882

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Site Reference ID/Investigator# 17665 Anaheim, California, United States
  • Site Reference ID/Investigator# 17367 Los Angeles, California, United States
  • Site Reference ID/Investigator# 17672 Los Angeles, California, United States
  • Site Reference ID/Investigator# 10381 Orlando, Florida, United States
View Trial Details
Completed

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

NCT00623649

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • The Liver INstitute at Methodist Dallas Dallas, Texas, United States
  • Alamo Medical Research San Antonio, Texas, United States
  • Ottawa Hospital - General Campus Ottawa, Ontario, Canada
  • Royal Victoria Hospital Montreal, Quebec, Canada
View Trial Details
Completed

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00743795

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Anaheim, California, United States
  • Los Angeles, California, United States
  • Newport Beach, California, United States
  • San Clemente, California, United States
View all 72 locations
View Trial Details

Related conditions